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Abstract
Background—Women who experience significant premenstrual symptoms differ in the extent to 
which these symptoms cause cyclical impairment. This study clarifies the type and number of 
symptoms that best predict premenstrual impairment in a sample of women undergoing 
prospective assessment for premenstrual dysphoric disorder (PMDD) in a research setting. Central 
research goals were to determine (1) which emotional, psychological, and physical symptoms of 
PMDD are uniquely associated with premenstrual impairment, and (2) how many cyclical 
symptoms optimally predict the presence of a clinically significant premenstrual elevations of 
impairment.
Methods—267 naturally cycling women recruited for retrospective report of premenstrual 
emotional symptoms completed daily symptom reports using the Daily Record of Severity of 
Problems (DRSP) and occupational, recreational, and relational impairment for 1–4 menstrual 
cycles (N = 563 cycles).
Results—Multilevel regression revealed that emotional, psychological, and physical symptoms 
differ in their associations with impairment. The core emotional symptoms of PMDD were 
predictors of impairment, but not after accounting for psychological symptoms, which were the 
most robust predictors. The optimal number of premenstrual symptoms for predicting clinically 
significant premenstrual impairment was four.
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Conclusion—Results enhance our understanding of the type and number of premenstrual 
symptoms associated with premenstrual impairment among women being evaluated for PMDD in 
research contexts. Additional work is needed to determine whether cognitive symptoms should 
receive greater attention in the study of PMDD, and to revisit the usefulness of the five-symptom 
diagnostic threshold.
Introduction
Premenstrual Dysphoric Disorder (PMDD) is characterized by clinically significant 
emotional symptoms emerging in the luteal phase of the menstrual cycle and resolving with 
the onset of menses (APA 2013). Roughly 5.5% of reproductive age women meet criteria for 
DSM-5 PMDD, which requires that at least five total symptoms per cycle follow this 
perimenstrual on-off pattern (Gehlert et al. 2009). Given the poor prospective validity of 
retrospectively-reported premenstrual symptoms (Rubinow et al. 1984), this cyclical 
symptom pattern must be confirmed by prospective daily symptom ratings. The recent 
inclusion of PMDD into DSM-5 was based on prospective epidemiological evidence for the 
existence of PMDD, experimental evidence for the pathophysiological role of ovarian 
steroid changes in PMDD, and evidence that PMDD is associated with significant societal 
burden and impairment (Epperson et al. 2012).
In addition to requiring the presence of marked premenstrual increases in five total 
premenstrual symptoms, the DSM-5 diagnostic criteria require that these symptoms are 
associated with “clinically significant distress or interference with work, school, usual 
activities, or relationships with others (e.g., avoidance of social activities; decreased 
productivity and efficiency at work, school, or home)” (APA 2013, p. 172). Therefore, in 
contrast to the preliminary PMDD criteria in DSM-IV-TR, which required impairment (APA 
2000, p. 774), life impairment is optional for DSM-5 PMDD diagnosis if clinically 
significant distress is present. On the other hand, the text of DSM-5 emphasizes the high 
prevalence of impairment in PMDD, and highlights impairment as an additional metric for 
determining the clinical significance of symptoms. Further, previous work demonstrates that 
the average impairment and reduced quality of life found in PMDD is similar in severity to 
that of dysthymic disorder, and is not much lower than that of major depressive disorder 
(MDD; Halbreich et al. 2003).
Study Aim 1: Identify Unique Content Predictors of Premenstrual Relational, Occupational, 
and Recreational Impairment
The DSM-5 definition of PMDD differentiates between three different types of impairment: 
occupational (at work, at home, or in school), recreational (in social activities and hobbies), 
and relational (in relationships with others), and previous studies have compared the 
prevalence of these three types of impairment. One cross-national study of women reporting 
severe premenstrual symptoms found that relational impairment in the home (specifically in 
relationships with one’s partner and/or children) was the most commonly reported type of 
impairment, followed by impairment in one’s social life more generally (mapping onto both 
recreational and relational impairment), and finally occupational impairment (Hylan et al. 
1999). As mentioned above, Halbreich et al. (Halbreich et al. 2003) compared the severity of 
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the three types of impairment in PMDD to that of women affected by dysthymia and MDD. 
While impairment in social activities and hobbies (recreational) was worse in PMDD than in 
dysthymia, marital and parental impairment (relational) was equally severe in both disorders. 
When comparing women with PMDD to women diagnosed with MDD, women with PMDD 
showed similar relational impairment in social, marital, and parental relationships, while 
women with MDD had greater impairment occupationally and recreationally. Therefore, 
there is some evidence that relational impairment may be a particularly strong feature of 
PMDD, followed by significant impairment in both recreational and occupational arenas.
No work to date has examined which specific PMDD symptoms are uniquely linked to 
which specific types of impairment. From a therapeutic standpoint, a clearer understanding 
of the types of symptoms that drive different types of impairment would allow more targeted 
interventions aimed at reducing the impact of specific symptoms that underlie particularly 
troubling types of premenstrual impairment. Therefore, the first aim of the present study is 
to examine the unique relationships between premenstrual elevations in each DSM-5 PMDD 
symptom and premenstrual elevations in relational, occupational, and recreational 
impairment.
Study Aim 2: Identify the Optimal Number of Cyclic Symptoms for the Prediction of 
Clinically Significant Premenstrual Impairment
In addition to investigating the nature of the symptoms that cause impairment, we also 
utilized a standardized PMDD diagnostic protocol and Receiver Operating Characteristic 
(ROC) curves to investigate the number of premenstrual symptoms that best predicts 
significant premenstrual impairment. Several research groups have described the DSM-5 
numerical requirement of five symptoms as “arbitrary” (Halbreich et al. 2003). Premenstrual 
functional impairment, though not required for diagnosis, can be seen as a “minimum 
threshold” at which diagnosis is necessary; should the number of symptoms required to 
predict premenstrual impairment be lower than the five symptoms required for DSM-5 
diagnosis, this would signal a need for further investigation about the appropriateness of 
reducing the threshold of 5 total symptoms. Indeed, a small number of studies are suggestive 
of the presence of significant premenstrual impairment in women with fewer than five total 
cyclical symptoms per cycle (Halbreich et al. 2003; Dean et al. 2006; Hartlage et al. 2012). 
Therefore, the present study uses a dimensional, cycle-level analysis to pinpoint the number 
of symptoms at which clinically significant functional impairment can be most accurately 
predicted.
Hypotheses
The following hypotheses were generated prior to data analysis:
Hypothesis 1: Premenstrual elevations in core emotional symptoms will uniquely 
predict concurrent premenstrual elevations in impairment of all types.
Hypothesis 2: Premenstrual elevations in secondary psychological symptoms 
(especially cognitive symptoms) will uniquely predict concurrent premenstrual 
elevations in occupational domains, but will not uniquely predict recreational and 
relational impairment.
Schmalenberger et al. Page 3
Psychol Med. Author manuscript; available in PMC 2017 July 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Hypothesis 3: Premenstrual elevations in physical symptoms will uniquely predict 
concurrent premenstrual elevations of recreational and occupational impairment, but 
will not predict relational impairment.
Hypothesis 4: When investigating the optimal number of symptoms to predict the 
presence of clinically significant premenstrual impairment, we predict that ROC 
curves will identify an optimal number of symptoms in a given cycle to predict 
concurrent impairment that is fewer than the five symptoms described in the DSM-5.
Methods
Between 2009 and 2015, naturally-cycling women ages 18–47 (M = 32.70, SD = 8.21) with 
regular cycles (21–35 days) were recruited through flyers and emails seeking women with 
premenstrual emotional symptoms. At a baseline visit, participants reported their medical 
and medication history and completed the SCID-I. Women were excluded for the following; 
an absence of self-reported premenstrual emotional symptoms; chronic medical disorders; 
histories of mania, substance dependence, or psychosis; any current SCID-I diagnosis; and 
certain medications (antidepressants, benzodiazepines, neuroleptics, or hormonal 
preparations). Next, eligible women completed daily reports of symptoms on the 24-item 
Daily Record of Severity of Problems (DRSP; Endicott et al. 2006) for 1–4 menstrual 
cycles. The DRSP measures all symptoms of DSM-5 PMDD, as well as 3 items assessing 
relational, occupational, and recreational impairment. Participants noted daily external 
events they believed to have impacted daily mood; days in which participants reported the 
occurrence of a stressor not caused by symptoms (e.g., “my wallet was stolen”) were coded 
as missing so as not to confound analyses (<1% of daily data). Participants mailed in forms 
weekly to minimize retrospective reporting.
Characterizing and Diagnosing Premenstrual Changes at the Cycle Level
The Carolina Premenstrual Assessment Scoring System (C-PASS; Eisenlohr-Moul et al. 
2016) is a standardized, computerized scoring system for diagnosing symptoms, cycles, and 
women with the DSM-5 PMDD symptom pattern on the basis of daily DRSP symptom 
ratings. For each symptom in each cycle, two C-PASS output variables were generated and 
used in the present study: (1) a dimensional variable representing the degree to which the 
symptom is elevated in the premenstrual week (days -7 to -1 where day -1 is the day prior to 
menses) relative to the following postmenstrual week (days 4 to 10, where day 1 is the first 
day of menses), and (2) a diagnostic decision variable (yes/no) reflecting whether or not the 
DSM-5 diagnostic criteria for a clinically significant premenstrual elevation in that symptom 
have been met. For each item, the percent premenstrual elevation variable was calculated as: 
the average rating during the premenstrual week minus the average rating during the 
postmenstrual week, divided by the range of scale used by the participant across all 
observations and multiplied by 100. The dichotomous diagnostic decision variable was 
determined on the basis of the following criteria (C-PASS symptom diagnostic criteria; 
Eisenlohr-Moul et al., 2016): First, the symptom must show a relative premenstrual 
symptom elevation that is greater than or equal to 30%. Second, the symptom must show 
absolute clearance, defined as a maximum postmenstrual week value less than or equal to 3 
(“Mild”). Third, the symptom must show sufficient absolute severity, defined as a 
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premenstrual week maximum severity level greater than or equal to 4 (“Moderate”). Finally, 
these clinically significant symptoms must show sufficient premenstrual duration, defined as 
at least two days in the premenstrual week in which the symptom is greater than or equal to 
4 (“Moderate”). If all four of these criteria are met, the symptom meets criteria for the 
symptom pattern described in DSM-5 PMDD in the present cycle. For the purposes of the 
present study, each DRSP item in each cycle received both a premenstrual elevation score 
and a dichotomous diagnostic decision. At the cycle level, we further calculated (1) the 
number of DSM-5 symptoms meeting the C-PASS diagnostic criteria outlined above, and (2) 
a binary outcome variable indicating whether or not at least one of the three impairment 
items met the four C-PASS criteria described above (coded as 0 = No,1 = Yes)1.
Symptom Content Domains—DSM-5 PMDD symptoms are heterogeneous. In our 
analyses of the nature of symptoms predicting impairment, we considered as predictors of 
impairment only the DRSP items that are not behaviorally consistent with impairment 
themselves in order to avoid criterion contamination. These decisions are outlined in Table 
1. The DSM-5 definition of PMDD offers the following structure for organizing the 
symptoms: Criterion B covers the core emotional symptoms (depression, hopelessness, 
worthlessness/guilt, anxiety, mood swings, rejection sensitivity, anger/irritability), while 
Criterion C includes the secondary psychological symptoms (less interest, difficulty 
concentrating, overwhelm/can’t cope, and out of control) along with the physical symptoms 
(lethargy/tired, breast tenderness, swelling and bloat, headache, and joint or muscle pain).
Analytic Plan
The first aim of the present study was to determine which DSM-5 premenstrual symptoms 
are most uniquely and robustly tied to premenstrual elevations in impairment. Analyses 
serving this purpose were carried out in two-level multilevel models (in SAS PROC 
MIXED) with cycles nested within women. Indices of premenstrual impairment elevation 
(relational, occupational, and recreational) were each predicted in a series of three 
increasingly complex models: (Model 1) a model predicting premenstrual elevation of 
impairment from premenstrual elevation of each of the core emotional symptoms, (Model 
2) a similar model adding premenstrual elevation of secondary psychological symptoms as 
additional predictors, and (Model 3) a model further adding premenstrual elevation of 
physical symptoms as predictors. As outlined in table 1, three symptoms listed within the 
DSM-5 diagnostic criteria (interpersonal conflict, sleeping more or trouble sleeping, and 
food cravings or increased appetite or overeating) were not included in these analyses, as 
they were considered to constitute impairment themselves and their inclusion may have led 
to criterion contamination2. These symptoms were only included as predictors in zero-order 
individual models.
1Some have argued that even mild premenstrual impairment is clinically significant; others have argued that impairment may persist 
into the postmenstrual phase even after the resolution of primary emotional symptoms. Therefore, all analyses were repeated using two 
alternative versions of the impairment criterion. The first alternative version removes the C-PASS requirement of absolute clearance 
(of impairment, in this case) during the postmenstrual week. The second alternative version alters the C-PASS threshold for absolute 
severity (premenstrual) from a rating of “4 – Moderate” to “3 – Mild”. Substitution of either of these alternative definitions for the 
impairment criterion did not substantively alter the results of ROC cut point selection of 4 symptoms presented in the Results section; 
therefore, the original definition of impairment cyclicity (using the original C-PASS criteria) was retained.
2Inclusion of sleeping symptoms (sleeping more, trouble sleeping) and eating symptoms (food cravings, overeating) in predictive 
models did not substantively alter the effects of other symptoms on impairment. Only premenstrual elevations in the symptom of 
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The second aim of the present paper was to estimate the optimal number of symptoms per 
cycle for predicting a pattern of premenstrual impairment consistent with the DSM-5 PMDD 
diagnosis (Eisenlohr-Moul et al. 2016). Corresponding analyses firstly included multilevel 
logistic models in SAS PROC GLIMMIX (cycles nested within women) predicting the 
presence of a C-PASS-defined PMDD pattern in any of the three impairment variables from 
the number of DSM-5 PMDD symptoms showing the same C-PASS-defined pattern in the 
same cycle. Next, receiver operating curves were constructed using the SAS ROCPLOT 
macro, and associated area under the curve (AUC) values were calculated for the prediction 
of the presence of significant cyclical impairment from the number of symptoms meeting 
criteria in the same cycle. Finally, the ROCPLOT macro was also used to calculate the 
efficiency criterion; this criterion is a prevalence (p)-weighted method of deriving an optimal 
cut point (Efficiency = p×Sensitivity + (1−p)×Specificity) for predicting the presence of a 
binary outcome (in this case, the presence of significant cyclical impairment). The 
percentage of cycles showing significant cyclical impairment in at least one of the three 
categories (occupational, recreational, or relational; as defined by the C-PASS criteria for a 
given symptom; see above) was 30.2%; therefore, the efficiency of each cut point was 
calculated as (.30 × Sensitivity) + (.70 × Specificity). For one, this efficiency method was 
chosen over methods (e.g., Youden index) that utilize a 50% base rate, since such a base rate 
is clearly inaccurate on the basis of our sample prevalence of cyclical impairment. This 
method was also chosen over methods that consider the cost benefit ratio of false positives 
and false negatives, because it is not yet clear that under- or over-diagnosis of premenstrual 
impairment has a greater cost.
Results
Two hundred and sixty-seven women contributed 563 cycles. At the cycle level, 149 cycles 
(26.4%) met C-PASS symptom criteria on at least one of the impairment items. 170 cycles 
(30.2% of the sample) received a PMDD diagnosis (i.e., >=5 cyclical symptoms, with at 
least one cyclical affective symptom). 200 women provided a sufficient number of cycles 
(i.e., at least two) to make a person-level diagnosis. At the person level, 38 women (19%) of 
women met C-PASS criteria for DSM-5 PMDD (as previously reported in Eisenlohr-Moul et 
al., 2016). As noted above, the prevalence of PMDD is roughly 5.5% of the population; the 
higher prevalence rate demonstrated here is indicative of the fact that women were recruited 
for retrospective self-report of premenstrual symptoms.
Which Symptoms Most Strongly Predict Severity of Premenstrual Impairment?
Results of multilevel regressions predicting the degree of premenstrual elevation in each 
type of impairment from the degree of premenstrual elevation in each of the DRSP items 
separately can be found in Table 2. Severity of premenstrual elevation in each of the DRSP 
items were significantly related to severity of each type of premenstrual impairment 
elevation in the same cycle. Next, in order to determine which DRSP items explained unique 
variance in the severity of each premenstrual impairment outcome, we conducted three-step 
sleeping more were a significant predictor of greater premenstrual impairment in occupational (Estimate = .035, SE = .010, p = .0010) 
and recreational (Estimate = .033, SE = .010, p = .0021), but not relational domains. Premenstrual increases in trouble sleeping (i.e., 
insomnia) and eating symptoms (food cravings, overeating) were not uniquely associated with any type of impairment.
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multiple regressions for each type of impairment to investigate which premenstrual symptom 
content domain is most tightly linked with premenstrual impairment elevations in the same 
cycle. Results of these models are summarized in the following sections.
Predicting Premenstrual Elevations in Occupational Impairment—In the first 
step of this multiple multilevel regression depicted in Table 3, greater premenstrual 
elevations in core emotional symptoms significantly predicted greater premenstrual elevation 
of occupational impairment in the same cycle. However, when secondary psychological 
symptoms were added as predictors, these core emotional symptoms were no longer 
predicted unique variance in occupational impairment—in contrast, all of the secondary 
psychological premenstrual symptoms uniquely predicted greater premenstrual occupational 
impairment over and above variance accounted for by the core emotional symptoms. When 
physical symptoms were added in the third step, all secondary psychological symptoms 
remained significant predictors of premenstrual occupational impairment, and several of the 
physical symptoms (lethargy/tiredness, swelling/bloating, and headache) also predicted 
unique variance in premenstrual occupational impairment. To summarize, secondary 
cognitive and psychological symptoms and physical symptoms, and not the core emotional 
symptoms, were uniquely linked with the degree of premenstrual occupational impairment 
in the same cycle.
Predicting Premenstrual Elevations in Recreational Impairment—In the first step 
of this multiple multilevel regression depicted in Table 4, greater premenstrual elevations in 
the core emotional symptoms predicted greater premenstrual elevation of recreational 
impairment. When secondary psychological symptoms were added, rejection sensitivity no 
longer predicted unique variance in recreational impairment, whereas each of the secondary 
psychological symptoms predicted greater premenstrual recreational impairment. When 
physical symptoms were added in the third step, all secondary psychological symptoms 
remained significant predictors of premenstrual recreational impairment, and of the core 
emotional symptoms only worthlessness/guilt remained a significant predictor. Two physical 
symptoms (headache and joint/muscle pain) also accounted for unique variance in 
recreational impairment. To summarize, the core emotional symptom of worthlessness/guilt, 
each of the secondary psychological symptoms, and some physical symptoms were uniquely 
linked with the degree of premenstrual impairment in recreational activities in the same 
cycle.
Predicting Premenstrual Elevations in Relational Impairment—In the first step of 
this multilevel regression depicted in Table 5, the core emotional symptoms significantly 
predicted greater premenstrual relational impairment. When secondary psychological 
symptoms were added, anxiety was no longer uniquely predictive of relationship 
impairment, and most of the secondary psychological symptoms (low interest, overwhelm, 
and feeling out of control) uniquely predicted greater premenstrual relational impairment. 
Adding physical symptoms in the third step did not significantly alter the results; physical 
symptoms were not uniquely linked to premenstrual relational impairment. Of note, two 
counterintuitive effects also emerged in the second step; when secondary psychological 
symptoms were added to the model, both hopelessness and poor concentration were 
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associated with less premenstrual relational impairment. To summarize, premenstrual 
relational impairment was uniquely predicted by the core emotional symptoms of 
worthlessness/guilt, rejection sensitivity, and anger/irritability, as well as the secondary 
psychological symptoms of low interest, overwhelm, and feeling out of control; none of the 
physical symptoms were uniquely predictive of premenstrual relational impairment.
What is the Optimal Total Number of DSM-5 Symptoms in a Given Cycle to Predict the 
Presence of Clinically Significant Premenstrual Impairment?
As expected, multilevel models revealed that the total number of symptoms meeting criteria 
in a given cycle was indeed predictive of whether or not that same cycle demonstrated 
significant premenstrual impairment (Estimate = .59, SE = .049, t(295) = 11.99, p < .0001; 
Odds Ratio = 1.76, 95% CI: 1.76 to 3.05). This odds ratio indicates that, for each one-
symptom increase in the number of total DSM-5 symptoms meeting C-PASS criteria per 
cycle, there is a 76% increase in the odds of meeting C-PASS criteria for impairment (in at 
least one impairment domain) in the same cycle. The area under the ROC curve was .90 
(95% CI: .87 to .92). Based on the efficiency criterion, the optimal number for predicting the 
presence of clinically significant cyclical impairment was 4 symptoms per cycle (see Figure 
1). Sensitivity decreased and specificity increased as the threshold total number of symptoms 
was increased; true positive (hit) rate decreased linearly from 3–6 symptoms (3: 87%, 4: 
80%, 5: 69%, 6: 58%), and false positive rate also decreased linearly from 3–6 symptoms (3: 
21%, 4: 12%, 5: 24%, 6: 6.4%). Therefore, despite the fact that the DSM-5 does not require 
the presence of cyclical impairment to make the diagnosis of PMDD, this ROC analysis 
suggests that the number of DSM-5 symptoms per cycle at which significant cyclical 
impairment might be optimally predicted (in a typical research sample of women recruited 
for retrospective report of premenstrual emotional symptoms) is four symptoms—fewer than 
the five symptoms per cycle currently required for the official diagnosis of DSM-PMDD. Of 
note, results were identical when the criteria for impairment cycles were adjusted to require 
both one emotional symptom meeting criteria and one impairment symptom meeting 
criteria.
Discussion
Recently, the American Psychiatric Association (2013) has acknowledged accumulating 
evidence regarding the validity and clinical significance of severe premenstrual affective 
symptoms in some women (Epperson et al. 2012) by making PMDD a full diagnostic 
category in DSM-5. Despite the fact that impairment is not strictly required for the diagnosis 
of PMDD in DSM-5, previous work has highlighted the high prevalence and impact of 
relational, recreational, and occupational impairment associated with premenstrual 
symptoms, with several studies indicating that PMDD is associated with impairment similar 
to that of other major affective disorders (Halbreich et al. 2003). The present study sought to 
provide information about the types and number of premenstrual symptoms that are most 
relevant to premenstrual impairment.
Results of hypothesis tests were mixed. Hypothesis 1 predicted that premenstrual elevations 
in core emotional symptoms would account for unique variance in concurrent premenstrual 
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elevations in all three types of impairment; this was partially supported, although only 
interpersonal emotions such as shame, anger, and rejection sensitivity were consistently 
associated with impairment, and these associations were often not significant after 
controlling for secondary psychological symptoms. Hypothesis 2 predicted that 
premenstrual elevations in secondary psychological symptoms (especially the cognitive 
symptoms) would predict unique variance in concurrent premenstrual elevations in 
occupational function, but not in relational or recreational domains. This hypothesis was also 
partially supported; secondary psychological symptoms were robustly and uniquely 
predictive of all three types of impairment over and above the influences of emotional and 
physical symptoms. Hypothesis 3 predicted that premenstrual elevations in physical 
symptoms would account for unique variance in concurrent premenstrual elevations of 
recreational and occupational impairment, but would not predict relational impairment. This 
hypothesis was supported; physical symptoms predicted the degree of recreational and 
occupational, but not relational, impairment. Finally, hypothesis 4 predicted that the optimal 
number of symptoms in a given cycle to predict concurrent impairment would be fewer than 
the five symptoms described in the DSM-5; this hypothesis was also supported, as four 
symptoms consistently emerged as the most defensible numeric threshold for predicting the 
presence of premenstrual impairment, even when a number of modifications were made to 
the impairment criterion.
Zero-order relationships revealed that premenstrual increases in all symptoms were 
significantly associated with premenstrual increases in all three types of impairment, 
indicating general covariation of premenstrual increases in distress, cognitive dysregulation, 
physical discomfort, and general life impairment among these women. Further, multiple 
multilevel regression models identified a variety of unique predictors of impairment in each 
domain. Surprisingly, although core emotional symptoms were often unique predictors of 
impairment outcomes in the first model, they usually became nonsignificant predictors with 
the inclusion of psychological and physical symptom predictors in later models. In contrast, 
results indicated that the secondary DSM-5 psychological symptoms predicted unique 
variance in premenstrual functional impairment in a given cycle over and above the variance 
accounted for by both emotional and physical symptoms. These secondary psychological 
symptoms could be broadly characterized as representing failures of executive cognitive 
functions, such as failures of attention (“difficulty concentrating”), failures of goal direction 
(“less interest in usual activities”; this may also reflect deficits in reward processing), and 
failures to initiate or sustain self-regulation (“overwhelmed, can’t cope” and “out of 
control”). The strong predictive validity of these items in the present study may indicate that 
the status of these psychological symptoms as “secondary” should be reconsidered in future 
iterations of PMDD diagnostic criteria. On the other hand, these results may simply indicate 
that core emotional symptoms exert their effects on premenstrual impairment by increasing 
expression of secondary psychological symptoms (i.e., mediation of primary emotional 
effects via secondary cognitive failures). Additional work with finer-grained measurements 
(e.g., ecological momentary assessment) across the symptomatic luteal phase will be needed 
in order to accurately model the direction of relationships between specific emotional, 
psychological, and physical symptoms and experiences of functional impairment.
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Among the emotional symptoms, premenstrual elevations in social emotional experiences, 
such as shame and guilt (“felt worthless, guilty”), rejection sensitivity, and anger and 
irritability consistently emerged as unique emotional predictors of premenstrual impairment 
across domains. These findings are consistent with previous work emphasizing the centrality 
of disturbed interpersonal experiences in women with PMDD (Hylan et al. 1999), and 
highlights the need for treatments that specifically target cyclical changes in interpersonal 
emotions, cognitions, and behaviors. In addition, both hopelessness and difficulty with 
concentration were linked with lower relational impairment, suggesting the possibility that 
interpersonal dysregulation also takes the form of social withdrawal in response to 
internalizing and cognitive symptoms. Meta-analytic analyses of RCT data demonstrate that 
cognitive behavioral therapies (CBT) can be helpful for PMDD (Busse et al. 2008; 
Kleinstäuber et al. 2012). However, the present results indicate that some women with 
PMDD may benefit from more targeted psychosocial interventions aimed specifically at 
resolving interpersonal affective and behavioral disturbances, which are often not directly 
addressed in CBT. Dialectical behavior therapy (DBT; Linehan, 2014), a skills-based 
intervention developed to treat pervasive emotional and interpersonal dysregulation such as 
that found in borderline personality disorder (BPD), could be useful to address deficits in the 
regulation of interpersonal emotions and behavior in PMDD. DBT includes traditional CBT 
skills for improving general emotion regulation; however, it also provides additional 
structure and skills for the therapist and the patient, including skills for promoting awareness 
of mood changes, maintaining the therapeutic relationship in the context of anger toward the 
therapist or urges to quit therapy, remaining functional in the face of emotional lability, and 
protecting key relationships in the context of strong emotional changes. Therefore, DBT 
may offer more targeted solutions for reducing premenstrual impairment–especially 
interpersonal impairment.
Consistent with the DSM-5 definition of PMDD as a psychiatric disorder, no physical 
symptoms were uniquely predictive of relational impairment in the present study, and 
physical symptoms had only small unique influences on recreational and occupational 
impairment. Severe physical symptoms in the form of dysmenorrhea must be ruled out prior 
to the making a diagnosis of DSM-5 PMDD; however, significant premenstrual physical 
complaints were common in the present study. Regardless, cycle-to-cycle variance in 
premenstrual physical symptoms does not appear to be strongly predictive of functional 
impairment in women being assessed for PMDD.
Regarding the number of symptoms predictive of impairment, results indicated that the 
number of DSM-5 symptoms meeting criteria per cycle (assessed for each cycle using the C-
PASS (Eisenlohr-Moul et al. 2016) strongly predicted the presence of cyclical, clinically 
significant impairment in the same cycle. ROC analyses using the efficiency method 
indicated that four symptoms per cycle yielded the best prediction of cyclical impairment. 
This finding suggests that the five symptom threshold specified in DSM-5 may be too 
stringent, especially considering that the mere presence of clinically significant cyclical 
distress, without impairment, is sufficient for DSM-5 diagnosis (APA 2013). While the 
threshold of four symptoms may be optimal for predicting the presence of cyclical problems 
in functioning, a threshold of four is almost certainly too stringent to allow many women 
with clinically significant cyclical distress but no impairment to receive a necessary PMDD 
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diagnosis. Therefore, the current DSM-5 threshold of five symptoms may lead to a “false 
negative” scenario among many women. These findings replicate previous findings 
(Hartlage et al. 2012), where four symptoms per cycle optimally predicted the presence of 
impairment. Notably, the present study replicated previous results despite utilizing a fine-
grained, multilevel analytic approach and a cut point analysis (i.e., efficiency method) that 
accounted for the actual base rate of cyclical impairment in our sample.
There are limitations of the present study that should be acknowledged. There were no 
alternative instruments employed to collect prospective daily ratings on distress and 
impairment in addition to the DRSP. When further validating the DSM-5 PMDD diagnosis, 
future studies should evaluate the PMDD DSM-5 criteria of five total cyclical symptoms per 
cycle against other measures of clinically-significant cyclical distress and impairment. In 
addition, the results of the current study can be generalized only to the population of women 
seeking assessment for PMDD in research contexts.
The present work has important implications for the definition and diagnosis of PMDD. 
Further reflection on the prevalence, diagnostic significance, and causes of impairment in 
this disorder are clearly warranted. The present results suggest the need for more refined 
behavioral treatments that target the emotional, cognitive, and behavioral factors linked with 
relational impairment. In addition, the total number of symptoms per cycle required to 
warrant diagnosis may be fewer than previously thought.
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Figure 1. 
ROC Curve Describing the Optimal Number of Total Cyclical DSM-5 Symptoms in a Given 
Cycle for Predicting Premenstrual Functional Impairment in the Same Cycle
Note. N = 563 Cycles; AUC = .90; Cut point Based on Efficiency Criterion = 4; Points are 
labeled by number of DSM-5 PMDD symptoms meeting C-PASS criteria.
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Table 2
Fixed Effects Estimates for Individual Predictor Models Predicting Degree of Premenstrual Elevation in Three 
Different Types of Impairment from Premenstrual Elevations in all other DRSP Items
Premenstrual Impairment Elevation
DRSP Item Occupational Recreational Relational
Premenstrual Elevation of Core Emotional Symptoms
Depression
.15*** .14*** .13***
Hopelessness
.15*** .14*** .13***
Worthlessness/Guilt
.14*** .14*** .14***
Anxiety
.13*** .13*** .15***
Mood Swings
.16*** .15*** .16***
Rejection Sensitivity
.16*** .15*** .17***
Anger/Irritability
.15*** .14*** .17***
Interpersonal Conflict
.14*** .15*** .20***
Premenstrual Elevation of Secondary Symptoms
Low Interest
.18*** .17*** .15***
Poor Concentration
.18*** .16*** .14***
Lethargic/Tired
.17*** .15*** .12***
Appetite/Overate
.12*** .12*** .12***
Food Cravings
.12*** .11*** .11***
Slept More
.16*** .14*** .11***
Trouble Sleeping
.12*** .12*** .10***
Overwhelm
.18*** .17*** .18***
Out of Control
.17*** .16*** .17***
Breast Tenderness
.10*** .10*** .12***
Swelling/Bloating
.12*** .12*** .12***
Headache
.09*** .11*** .08***
Joint/Muscle Pain
.12*** .13*** .11***
Note.
*p < .05,
**p < .01,
***p < .001.
Predictors are standardized using the full sample; therefore, estimates can be interpreted as the impact of a one standard-deviation increase in the 
predictor on premenstrual elevation of the outcome (e.g., Estimate = .15 can be interpreted as meaning that a one standard deviation increase in the 
predictor is associated with a 15% greater premenstrual elevation of impairment over one’s follicular baseline).
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